title: The safety of tiotropium--the FDA's conclusions.
authors.affiliation: Division of Pulmonary, Allergy, and Rheumatology Products, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
authors.forename: Theresa M
authors.initials: TM
authors.lastname: Michele
authors.forename: Simone
authors.initials: S
authors.lastname: Pinheiro
authors.forename: Solomon
authors.initials: S
authors.lastname: Iyasu
mesh_terms: D001993:Bronchodilator Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000401:mortality; D002986:Clinical Trials as Topic; D017277:Drug Approval; D006801:Humans; D015201:Meta-Analysis as Topic; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D012602:Scopolamine Derivatives / Q000009:adverse effects* / Q000627:therapeutic use; D000069447:Tiotropium Bromide; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D001993:Bronchodilator Agents; D012602:Scopolamine Derivatives; D000069447:Tiotropium Bromide